Introduction
Proliferation, apoptosis, and differentiation of hematopoietic progenitor cells are regulated by hematopoietic cytokines, including interleukin (IL)-3 and erythropoietin, as well as through direct interaction with the bone marrow microenvironment composed of stromal cells and extracellular matrix components, such as fibronectin. The hematopoietic cytokine receptors, including the IL-3 receptor (IL-3R), mainly couple with a member of the JAK family of tyrosine kinases, Jak2, which phosphorylates the receptors and thereby recruits various signaling molecules through interaction between the tyrosine phosphorylated docking sites in the receptors and the SH2 domains in the signaling molecules (Ihle, 1995) . Thus, members of the STAT family of latent transcription factors, mainly STAT5, are recruited to the cytokine receptors through its SH2 domain to become phosphorylated and activated by Jak2. The small GTPase Ras, which is inactive in the GDP-bound form, is also activated by the exchange of GDP for GTP, a reaction which is catalysed by guanine nucleotide exchange factors (GEFs) recruited to the activated cytokine receptors (Bar-Sagi and Hall, 2000; Takai et al., 2001) . The activated GTP-bound form of Ras then activates the Raf-1/MEK/Erk signaling cascade leading to proliferation of cells. The activated form of Ras also binds the p110 catalytic subunit of phosphatidylinositol 3 0 -kinase (PI3K) and activates its catalytic activity. A serine/threonine kinase, Akt, is activated downstream of PI3K to regulate various cellular processes such as apoptosis, cell cycle progression, transcriptional regulation, and glucose uptake by phosphorylating various signaling molecules, including Bad, p21, p27, the forkhead family transcription factors, and glycogen synthase kinase-3 (Brazil et al., 2004) .
The Philadelphia chromosome, detected in more than 95% of patients with chronic myeloid leukemia (CML) and 30-40% of acute lymphoblastic leukemia, results in the fusion of sequences from the BCR and ABL genes (Faderl et al., 1999; Clarkson et al., 2003; Goldman and Melo, 2003) . The BCR/ABL fusion product is an activated tyrosine kinase that confers survival and proliferation advantages to hematopoietic cells, thus contributing to leukemogenesis. BCR/ABL constitutively activates various intracellular signaling pathways that normally play roles in regulation of hematopoiesis by hematopoietic cytokines and other extracellular stimuli (Faderl et al., 1999; Clarkson et al., 2003; Goldman and Melo, 2003) . Thus, BCR/ABL has been shown to activate the Ras/Raf-1/Erk and PI3K/Akt signaling pathways as well as STAT5.
We previously found that hematopoietic cytokines, IL-3 and Epo, as well as BCR/ABL activate Rap1 in hematopoietic cells (Arai et al., 2001; Mizuchi et al., 2005) . Rap1 is a small GTPase of the Ras family, which was initially identified as a homolog of Ras (Pizon et al., 1988) and was also identified independently by its ability to induce a flat revertant phenotype in K-Ras-transformed cells (Kitayama et al., 1989) . Later studies postulated that Rap1 interferes with Ras-effector signaling by the sequestration of Raf-1 and other Ras effectors within an inactive complex (Bos et al., 2001; Stork, 2003) . However, more recent studies have demonstrated that Rap1, like Ras, can activate the MEK/Erk signaling pathway through activation of BRaf, a member of the Raf family kinase, in several cell types (Stork, 2003) . Thus, depending on cell types, Rap1 may activate the MEK/Erk signaling pathway through B-Raf or may reduce its activation through its inhibitory effect on Raf-1. Similarly, recent studies have shown that Rap1 may also interact with the Ras effector PI3K and show a negative or positive effect on activation of the PI3K/Akt pathway depending on cell types and stimuli (Tsygankova et al., 2001; Wang et al., 2001; Lou et al., 2002; Christian et al., 2003) . In our previous study, we found that IL-3 as well as Epo activates b1 integrin through Rap1 and induces hematopoietic cell adhesion, which agrees with recent studies showing that Rap1 plays important roles in regulation of cell adhesion through various integrins (Arai et al., 2001; Bos et al., 2001; Stork and Dillon, 2005) . However, the roles Rap1 plays in activation of downstream signaling pathways, including those involving B-Raf, Raf-1, MEK, Erk, and Akt1, in cells stimulated by IL-3 or BCR/ABL have largely remained to be examined. The effects of Rap1 activation on proliferation and apoptosis of these cells as well as the possible involvement of Rap1 in regulation of adhesion of cells expressing BCR/ ABL have also remained obscure.
By abrogating Rap1 activation by forced expression of SPA-1, a Rap1-specific GAP (Kurachi et al., 1997) , we demonstrate in the present study that Rap1 plays a role in activation of the B-Raf/MEK/Erk pathway and Akt in cells stimulated with IL-3 or expressing BCR/ ABL. We further demonstrate that Rap1 plays roles in induction of cell proliferation and prevention of apoptosis in these cells and that Rap1 at least partly mediates BCR/ABL-induced adhesion of hematopoietic cells.
Results
SPA-1 specifically inhibits activation of Rap1 and B-Raf in cells stimulated with IL-3 or expressing BCR/ABL To explore the roles Rap1 plays in signaling from cytokine receptors and BCR/ABL, we established SPA-1 expressing clones of Ton.B210 cells, an IL-3-dependent cell line that inducibly expresses BCR/ABL in the presence of Dox (Klucher et al., 1998) . This is because SPA-1, unlike dominant-negative mutants of Rap1, very strongly inhibits Rap1 in cells through its GAP activity specific for Rap1 (Kurachi et al., 1997; van den Berghe et al., 1997; Mizuchi et al., 2005) . As shown in Figure 1a , the expression of exogenous SPA-1 tagged with the Myc epitope in the selected clone Ton.B210/SPA-1 was confirmed by anti-Myc immunoblotting. Anti-SPA-1 immunoblotting further showed that the expression level of endogenous SPA-1 was much lower than that of heterogeneously expressed SPA-1 in Ton.B210/SPA-1 cells. Ton.B210/SPA-1 expressed a higher level of BCR/ ABL than the parental Ton.B210 cells, and the expression level of BCR/ABL in Ton.B210/SPA-1 at 0.1 mg/ml Dox was comparable with that in Ton.B210 at 1 mg/ml Dox (Figure 1a ). Other two SPA-1-expressing clones examined also expressed higher levels of BCR/ ABL than Ton.B210 (data not shown). Therefore, Figure 1 SPA-1 expression specifically abrogates Rap1 activation and mitigates B-Raf activation induced by IL-3 or BCR/ABL. (a) Ton.B210 (Cont.) or Ton.B210/SPA-1 cells (SPA-1), a clone of Ton.B210 expressing Myc-tagged SPA-1, were cultured with indicated concentrations of Dox for 24 h. Cells were lysed and total cell lysates were subjected to anti-Abl blotting followed by reprobing with anti-Myc, anti-SPA-1, and anti-a-tubulin, as indicated. (b-e) Ton.B210 (Cont.) or Ton.B210/SPA-1 cells (SPA-1) were starved overnight from IL-3 in the presence Dox at 1 or 0.1 mg/ml, respectively, where indicated. Then, cells were left unstimulated or stimulated with 10 U/ml IL-3 for 5 min, as indicated, and lysed. Activated Rap1 (b) or Ras (c) was affinity purified from cell lysates by specific GST-fusion protein probes, as described under Materials and methods. Eluates from precipitates were subjected to Western blot analyses with relevant antibodies to detect activated Rap1 (Rap1-GTP) or Ras (Ras-GTP), as indicated. Total cell lysates were also analysed by Western blot analysis for cellular contents for total Rap1 and Ras, as indicated, in lower panels. Relative amounts of activated GTPases were quantitated by densitometric analysis, normalized by total amounts of GTPases, and indicated below each lane. Cell lysates were also immunoprecipitated with anti-B-Raf (d) or anti-Raf-1 (e) and subjected to the in vitro kinase assay using GST-MEK as substrate, as described under Materials and methods. The reaction samples were analysed by Western blot analysis with antiphospho-MEK antibody, followed by reprobing with anti-GST and anti-B-Raf (d) or anti-Raf-1 (e), as indicated. Relative B-Raf and Raf-1 activities were quantitated by densitometric analysis, normalized by amounts of B-Raf and Raf-1, respectively, and indicated.
Rap1 activation by BCR/ABL and IL-3 A Jin et al although the reason for the higher expression levels of BCR/ABL in SPA-1 expressing clones than in parental cells is unknown, we induced the BCR/ABL expression using 1 and 0.1 mg/ml of Dox in Ton.B210 and Ton.B210/SPA-1 cells, respectively, in following experiments unless described otherwise. We first examined whether SPA-1 expressed in Ton.B210/SPA-1 cells inhibits Rap1 activation by IL-3 stimulation or by BCR/ABL expression. In accordance with our previous reports, IL-3 stimulation as well as the induction of BCR/ABL expression by Dox treatment activated Rap1 in Ton.B210 cells (Figure 1b) (Arai et al., 2001; Mizuchi et al., 2005) . On the other hand, the SPA-1 expression in Ton.B210/SPA-1 cells not only reduced the basal level of Rap1-GTP significantly but also inhibited Rap1 activation by IL-3 and BCR/ABL almost completely (Figure 1b) . In contrast, SPA-1 expression in Ton.B210/ SPA-1 cells did not significantly affect Ras activation by IL-3 or BCR/ABL, as shown in Figure 1c .
As B-Raf is known to be activated by Rap1 and has been implicated in downstream signaling from Rap1 (Stork, 2003) , we next examined the effect of SPA-1 expression on B-Raf. In accordance with our previous report (Mizuchi et al., 2005) , IL-3 stimulation as well as the induction of BCR/ABL expression by Dox treatment activated B-Raf in Ton.B210 cells (Figure 1d ). The SPA-1 expression in Ton.B210/SPA-1 cells partly inhibited activation of B-Raf by IL-3 and BCR/ABL in repeated experiments (Figure 1d and data not shown). Notably, however, the inhibitory effect of SPA-1 on B-Raf activation was not as remarkable as that on Rap1 activation. In contrast, the SPA-1 expression in Ton.B210/SPA-1 cells did not inhibit activation of Raf-1 by IL-3 or BCR/ABL in repeated experiments and in fact increased the Raf-1 activity in some experiments as shown in Figure 1e .
Inactivation of Rap1 inhibits IL-3-or BCR/ABL-induced activation of the MEK/Erk signaling pathway and Akt
To explore the signaling pathways activated downstream of Rap1 in cells stimulated with IL-3 or expressing BCR/ABL, we examined the effects of SPA-1 on activation of the MEK/Erk, PI3K/Akt, and STAT5 signaling pathways, known to be activated by IL-3 as well as by BCR/ABL. Western blot analyses using activation-specific antibodies showed that activation of MEK, Erk, and Akt by IL-3 stimulation or by BCR/ABL expression in Ton.B210/SPA-1 cells was significantly reduced as compared with that in Ton.B210 cells (Figure 2a ). On the other hand, tyrosine phosphorylation of STAT5, a direct substrate for IL3R-coupled Jak2 or BCR/ABL, was induced similarly in Ton.B210/ SPA-1 and Ton.B210 cells. In addition to confirming the inhibitory effects of SPA-1 on IL-3-induced activation of MEK, Erk, and Akt, a time-course experiment with IL-3 stimulation further revealed that the inhibitory effects were observed as early as 1 min after stimulation ( Figure 2b ). We also examined the effects of SPA-1 on BCR/ABL-activated signaling pathways by a Dox dose-response experiment. As shown in Figure 2c , Ton.B210/SPA-1 cells cultured with 0.1 mg/ml Dox express a comparable level of BCR/ABL with Ton.B210 cells cultured with 1 mg/ml Dox. However, activation of MEK, Erk, and Akt in Ton.B210/SPA-1 cells at 0.1 mg/ ml Dox was significantly less than that in Ton.B210 cells at 1 mg/ml Dox. Moreover, when cells were cultured with 1 mg/ml Dox, BCR/ABL, although expressed at a remarkably higher level in Ton.B210/SPA-1 cells than in Ton.B210 cells, activated MEK, Erk, and Akt to significantly lesser extents in Ton.B210/SPA-1 cells than in Ton.B210 cells. In contrast, tyrosine phosphorylation of STAT5 induced by IL-3 or by BCR/ABL was not significantly affected by SPA-1 expression in Ton.B210/ SPA-1 cells (Figure 2b and c). Although similar results were obtained in two other Ton.B210 clones expressing SPA-1, we further examined pooled clones transfected with the SPA-1 expression plasmid or the empty vector plasmid to confirm the effects of SPA-1 on IL-3-and BCR/ABL-induced signaling events. As shown in Figure  2d and e, SPA-1 inhibited IL-3-or BCR/ABL-induced activation of MEK, Erk, and Akt, without showing any significant effect on induction of STAT5 tyrosine phosphorylation in the mixed clones expressing SPA-1. These data suggest that Rap1 plays a significant role in activation of the MEK/Erk and Akt signaling pathways in response to IL-3 stimulation or BCR/ABL expression.
Rap1 inactivation inhibits IL-3-or BCR/ABL-dependent proliferation and survival of cells
Inhibition of Rap1 by SPA-1 expression was shown to have inhibitory effects on activation of MEK/Erk and Akt signaling pathways, both of which are expected to play important roles in regulation of cell proliferation and survival. Thus, we next examined the effects of Rap1 inactivation on induction of proliferation and suppression of apoptosis by IL-3 or BCR/ABL. A doseresponse growth curve experiment with IL-3 showed that Ton.B210/SPA-1 cells proliferated slightly more slowly than Ton.B210 cells when cultured with 2.5 or 0.5 U/ml IL-3 (Figure 3a ). At 0.1 U/ml IL-3, while Ton.B210 cells slowly proliferated, Ton.B210/SPA-1 cells did not show any proliferation. Viability of Ton.B210/SPA-1 cells at 0.1 U/ml IL-3 was also remarkably lower than that of Ton.B210 cells (Figure 3b ). These data suggest that Rap1 activation may play a crucial role in induction of cell proliferation and inhibition of apoptosis at low suboptimal concentrations of IL-3.
On the other hand, a dose-response growth curve experiment with Dox showed that Ton.B210/SPA-1 cells proliferated significantly more slowly than Ton.B210 cells at each concentration (Figure 3c ). Viability of Ton.B210/SPA-1 cells was also significantly lower than that of Ton.B210 cells at each Dox concentration (Figure 3d ). These differences between Ton.B210/SPA-1 and Ton.B210 cells were more remarkable when they were cultured with Dox than with IL-3, even though BCR/ABL is expressed at a significantly higher level in Ton.B210/SPA-1 cells than in Ton.B210 cells at each concentration of Dox (Figure 2d ). Thus, these results suggest that Rap1 may play more crucial roles in regulation of proliferation and apoptosis when these cells are stimulated with BCR/ABL than with IL-3. Consistent with this, a flow cytometric analysis of cellular DNA contents showed that a substantial portion of Ton.B210/SPA-1 cells underwent apoptosis and exhibited sub-G1 DNA contents when cultured with 0.1 mg/ml Dox and, thus, expressing BCR/ABL at a level comparable with that in Ton.B210 cells cultured with 1 mg/ml Dox (Figure 3e ). Moreover, when cultured at 0.01 mg/ml Dox, Ton.B210/SPA-1 cells underwent massive apoptosis, whereas only a small portion of Ton.B210 cells underwent apoptosis. These observations, thus, raise an interesting possibility that, as compared with IL-3, BCR/ABL is more dependent on Rap1 for transduction of signals required for induction of cell proliferation and prevention of apoptosis. 
Rap1 activation by BCR/ABL and IL-3 A Jin et al
The pooled clones expressing SPA-1 also showed significantly reduced proliferation and viability as compared with the mixed control clones when cultured with various concentrations of IL-3 or Dox (data not shown). Furthermore, although the effect of SPA-1 on apoptosis in the pooled clones was not as remarkable as that observed in the Ton.B210/SPA-1 clone selected for the highest SPA1 expression level, apoptosis was significantly induced selectively in SPA-1 expressing clones when cultured with a low concentration of Dox (Figure 3f ).
Rap1 inactivation partly inhibits BCR/ABL-induced cell adhesion
We have previously shown that Rap1 plays an important role in activation of integrin-mediated hematopoietic cell adhesion in response to cytokine stimulation (Arai et al., 2001) . Although it still remains controversial, BCR/ABL has also been reported to activate integrin-mediated hematopoietic cell adhesion (Bazzoni et al., 1996; Kramer et al., 1999; Wertheim et al., 2002) . Thus, we next explored the possibility that Rap1 activation mediates BCR/ABL-induced cell adhesion in leukemic cells. We first examined the role of BCR/ABL in regulation of adhesion of leukemic cells. As shown in Figure 4a , inhibition of the BCR/ABL kinase activity by imatinib significantly reduced adhesion of K562 cells, a CML cell line in which we previously showed that imatinib significantly inhibited Rap1 activity (Mizuchi et al., 2005) . A similar result was obtained in primary leukemic blasts from a patient with CML in blast crisis (Figure 4a ). Consistent with these results, induction of BCR/ABL expression by Dox treatment increased adhesion of Ton.B210 cells (Figure 4b ). Moreover, imatinib partially but significantly inhibited adhesion of Ton.B210 cells expressing BCR/ABL. We finally examined the adhesion of Ton.B210/SPA-1 cells. As shown in Figure 4c , either in the presence or absence of Dox, the level of adhesion of Ton.B210/SPA-1 cells was significantly lower than that of Ton.B210 cells. Nevertheless, it was found that imatinib partly inhibited the adhesion of Ton.B210/ SPA-1 cells in the presence of Dox. Consistent with these results, the adhesion level of pooled clones of Ton.B210 transfected with the SPA-1 expression plasmid was significantly lower than that of pooled control clones and was decreased by pretreatment with imatinib ( Figure 4d ). Together, these results suggest that Rap1 activated by BCR/ABL at least partly mediates enhancement of cell adhesion in BCR/ABL-expressing leukemic cells.
Discussion
We previously found that hematopoietic cytokines activate Rap1 to induce b1-integrin-mediated cell adhesion and that BCR/ABL also activates Rap1 as well as B-Raf in hematopoietic cells to stimulate the MEK/Erk signaling pathway (Arai et al., 2001; Mizuchi ) and Ton.B210/SPA-1 (SPA-1) cells were washed three times and cultured for 24 h in medium containing indicated concentrations of Dox or 10 U/ml IL-3. Cells were then stained with propidium iodide, and DNA content was analysed by flow cytometry. Percentages of cells undergoing apoptosis, evaluated by quantitating hypodiploid, sub-G1 DNA content, are indicated. (f) Mixed Ton.BaF3 clones transfected with the SPA-1 expressing plasmid (SPA-1) or the empty vector (Cont.) were washed and cultured for 24 h in medium containing 10% Wehi-conditioned medium, 0.5 U/ml IL-3, or indicated concentrations of Dox. Cells were then stained and analysed as described in the legend for (e).
Rap1 activation by BCR/ABL and IL-3
A Jin et al et al., 2005) . To extend these observations, we explored the effects of Rap1 activation in hematopoietic cells by specifically abrogating Rap1 activation by the forced expression of SPA-1 (Figure 1 ). In this experimental system, activation of the MEK/Erk signaling pathway and Akt by IL-3 stimulation or BCR/ABL expression was significantly inhibited by inactivation of Rap1, while that of B-Raf was moderately inhibited (Figure 1 and 2). Consistent with this, cell proliferation and survival dependent on IL-3 stimulation were significantly reduced by inhibition of Rap1 and, notably, those dependent on BCR/ABL expression were more remarkably inhibited (Figure 3 ). Furthermore, it was demonstrated that BCR/ABL-induced cell adhesion at least partly through mechanisms dependent on its kinase activity and Rap1 activation (Figure 4 ). Together, these results strongly support the model in which BCR/ABL as well as the IL-3R activates Rap1 to stimulate proliferation and survival of hematopoietic cells through the B-Raf/MEK/Erk and PI3K/Akt signaling pathways as well as to induce cell adhesion through integrins ( Figure 5 ). Activation of the MEK/Erk signaling pathway by IL3 stimulation or by BCR/ABL expression was significantly inhibited by SPA-1, while it only moderately inhibited activation of B-Raf and did not show any inhibitory effect on Raf-1. This is in agreement with the previous observations that Rap1 does not activate Raf-1 but may in fact inhibit Raf-1 activation by Ras in some types of cells (Stork, 2003) . Intriguingly, activation of Raf-1 by IL-3 stimulation or BCR/ABL expression was augmented in some experiments, as shown in Figure 1e . However, the significance of this observation has remained to be determined, because it was not consistently observed in all the repeated experiments. Nevertheless, these results strongly suggest that B-Raf plays a more important role than Raf-1 in activation of the MEK/Erk signaling pathway downstream of the IL-3R and BCR/ABL, which is in agreement with previous observations in B cells stimulated through the B-cell antigen receptor (Brummer et al., 2002) . It should be also noted that B-Raf was inhibited only moderately by SPA-1, whereas the activation of Rap1 or the MEK/Erk signaling pathway was inhibited completely or more significantly by SPA-1, respectively. This is most likely because B-Raf possesses an intrinsically high background kinase activity and is activated also by Ras ( Figure 5 ) (Papin et al., 1996; Wellbrock et al., 2004) . It is further speculated that activation by both Ras and Rap1 is required for the B-Raf activity to reach a high threshold level for efficient stimulation of the MEK/Erk signaling pathway. Thus, inhibition of either Ras or Rap1 alone may be necessary to reduce the MEK/Erk signaling pathway effectively to inhibit cell proliferation.
Previously, Garcia et al. (2001) reported that both Rap1/B-Raf and Ras/Raf-1 pathways play roles in Erk activation in a human leukemia cell line, UT7, washed out from IL-3 and cultured with or without 5 mM imatinib, as indicated, for 6 h. Cells were then subjected to the cell adhesion assay. (c) Ton.B210 (Cont.) or Ton.B210/SPA-1 (SPA-1) cells, cultured in the presence or absence of Dox, as indicated, were washed out from IL-3 and cultured with or without 5 mM imatinib, as indicated, for 6 h, before subjected to the cell adhesion assay. (d) Mixed Ton.B210 clones transfected with the SPA-1 expressing plasmid (SPA-1) or the empty vector (Cont.) were cultured with 1 mg/ml Dox for 24 h. Cells were then washed out from IL-3 and cultured with or without 5 mM imatinib, as indicated, in the presence of 1 mg/ml Dox for 6 h, before subjected to the cell adhesion assay.
A Jin et al stimulated with the hematopoietic cytokine thrombopoietin (TPO). They further demonstrated that, while the Ras/Raf-1 pathway was responsible for transient Erk activation, the Rap1/B-Raf pathway induced sustained Erk activation, which was required for megakaryocytic differentiation induced by TPO. The ability of TPO to activate Rap1 to mediate sustained Erk signaling agrees with the observation that several hours of stimulation with TPO are required for activation of Rap1 and is similar to that seen in the neuronal differentiation of PC12 cells stimulated by NGF (Garcia et al., 2001; Stork, 2003; Stork and Dillon, 2005) . On the other hand, IL-3 stimulation rapidly induces activation of Rap1 (Arai et al., 2001) , and Rap1 inactivation by SPA-1 inhibited the transient early Erk activation (Figure 2b) . The difference in time course of activation of Rap1-mediated signaling between IL-3 and TPO may respond to the difference in signaling for proliferation and differentiation, although the molecular mechanisms responsible remain to be examined.
The present study revealed that activation of Akt by IL3 stimulation or by BCR/ABL expression in hematopoietic cells was also remarkably inhibited by SPA-1. Previous reports have implicated Rap1 as a positive or a negative regulator of Akt activation in various types of cells stimulated with different stimuli (Tsygankova et al., 2001; Wang et al., 2001; Lou et al., 2002; Christian et al., 2003) . Although the molecular mechanisms underling these effects have not been elucidated, Rap1 has been proposed to bind PI3K through its effector-binding region, which is identical with that of Ras (Downward, 1997; Bos et al., 2001) . Different effects of Rap1 on Akt activation may be due to differences in phosphorylation of Rap1, which has been shown to play crucial roles in modulation of the PI3K/Akt signaling pathway (Tsygankova et al., 2001; Lou et al., 2002) . Although the molecular mechanism has remained to be examined, the present study strongly implicates Rap1 as a positive regulator for activation of the PI3K/Akt signaling pathway, which plays important roles in regulation of cell proliferation and apoptosis (Brazil et al., 2004) .
Consistent with its inhibitory effects on activation of the MEK/Erk signaling pathways and Akt, SPA-1 significantly reduced proliferation and survival of cells induced by IL-3 stimulation or BCR/ABL expression (Figure 3) . Importantly, the inhibitory effects were more remarkably observed for BCR/ABL-dependent than IL-3-dependent proliferation and survival. This suggests that, as compared with IL-3, BCR/ABL is more dependent on Rap1-mediated signaling pathways, which agrees with the idea that cancer cells depend on a few highly activated signaling pathways and are particularly sensitive to inhibition of these pathways (Klein et al., 2005) . This also agrees with previous observations that PI3K inhibitors exerted a selective antileukemic effect in CML cells while sparing normal counterparts and synergized with imatinib to inhibit growth of human CML cells (Skorski et al., 1995; Klejman et al., 2002; Marley et al., 2004) . Thus, the present study proposes that the Rap1-mediated signaling pathways may represent attractive targets for novel therapies for BCR/ABLexpressing leukemias.
In this study, Rap1 was implicated in activation of hematopoietic cell adhesion in BCR/ABL-expressing cells, which is consistent with our previous finding that hematopoietic cytokines, including IL-3, induce b1-integrin-mediated cell adhesion through activation of Rap1 (Arai et al., 2001) . The increase in cell adhesion to fibronectin induced by BCR/ABL in this study is also in agreement with previous studies demonstrating the increased b1-integrin-mediated adhesion of various hematopoietic cell lines expressing BCR/ABL as well as of primary hematopoietic progenitor cells from CML patients (Bazzoni et al., 1996; Kramer et al., 1999; Wertheim et al., 2002) . On the other hand, BCR/ABL has also been reported to decrease adhesion of primary CML progenitors as well as normal hematopoietic progenitor cells when ectopically expressed (Gordon et al., 1987; Verfaillie et al., 1992; Ramaraj et al., 2004) . In these studies, however, adhesion was evaluated indirectly by counting the number of colonies initiated by adherent cells after several weeks of culture. The discrepancy may also be caused by other differences in experimental conditions, such as the presence or absence of hematopoietic cytokines, because BCR/ABL was reported to inhibit cell adhesion induced by hematopoietic cytokines and growth factors (Bhatia et al., 2001) . Consistent with this, in a very recent study by Barnes et al. (2005) , BCR/ABL increased adhesion of IL-3-dependent 32D cell line in a dose-dependent manner in the absence of IL-3 but had an inhibitory effect on IL-3-induced adhesion in a dose-independent manner. Thus, as compared with parental cells, adhesion of 32D cells expressing BCR/ABL at low levels was either increased or reduced in the absence or presence of IL-3, respectively. These observations are also in accordance with our hypothesis that Rap1 mediates inside-out signaling that regulates integrin-mediated cell adhesion downstream of both hematopoietic cytokines and BCR/ABL, because the constitutive activation of this pathway by BCR/ABL would elicit negative regulatory mechanisms that diminish the effect of cytokines. It should be also noted that, in the present study, as well as in previous studies (Wertheim et al., 2002; Ramaraj et al., 2004) , BCR/ABL has been shown to disturb cell adhesion at least partly in a kinase activity-independent manner, which is most likely related to the abilities of BCR/ABL to bind and modify actin cytoskeleton (Wertheim et al., 2003) . Effects of Rap1-mediated disturbance in cell adhesion on proliferation and survival of BCR/ABL-expressing cells need to be addressed in future studies.
Recently, accumulating evidence has implicated Rap1 in pathogenesis of malignancies including leukemias (Hattori and Minato, 2003; Kometani et al., 2004; Stork and Dillon, 2005) . Most significantly, it was found that SPA-1-deficient mice developed myeloproliferative disorders resembling CML in chronic phase and in blast crisis (Ishida et al., 2003) . Both bone marrow preleukemic progenitors and overt leukemic blast cells in SPA-1/ mice showed markedly increased Rap1GTP levels, accompanied by a constitutive ERK activation. It was further demonstrated that the retroviral transduction of an activated mutant of Rap1, RapE63, into the normal bonemarrow progenitors significantly enhanced their expansion, whereas the overexpression of SPA-1 strongly suppressed it, confirming a positive role of Rap1 in proliferation of hematopoietic progenitors (Ishida et al., 2003) . Intriguingly, in a leukemic cell line established from a SPA-1 deficient mouse with the disorder resembling CML in blast crisis, SPA-1 did not significantly affect the constitutive Erk activation and the proliferation rate, which were most likely due to constitutive activation of Ras, but abrogated the leukemogenic activity in vivo. This suggests that persistent Rap1 signaling contributes to leukemogenesis through activation of signaling pathways not shared with Ras, which may include those involved in integrin activation. Taken together with these observations, the present study strongly suggests that Rap1 may play crucial roles in leukemogenesis by BCR/ABL and warrants further investigation as a possible target for novel therapies for CML and Ph-positive ALL.
Materials and methods

Cells and reagents
A clone of murine IL-3-dependent BaF3 cells transfected with a BCR/ABL cDNA under the control of a tetracyclineinducible promoter, TonB210, was kindly provided by Dr George Q Daley (Klucher et al., 1998) and cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and 10% Wehi3B conditioned medium as the source of IL-3. A human CML cell line, K562, was maintained in RPMI 1640 medium supplemented with 10% FCS.
Leukemic blasts were isolated from a CML patient in myeloid crisis. Informed consent was provided according to the Declaration of Helsinki, and the study was approved by the ethical committee of Tokyo Medical and Dental University. Mononuclear cells were isolated by centrifugation through Ficoll-Hypaque, washed in RPMI 1640 medium supplemented with 10% FCS, and cryopreserved. The percentage of blasts in the sample determined morphologically was more than 90%.
An anti-SPA-1 monoclonal antibody was generated by immunizing rats with baculoviral recombinant mouse SPA-1. Spleen cells from the immunized rats were fused with SP2/0 cells, and the hybridoma producing anti-SPA-1 (clone 2-22-9) was selected by Western blot analysis using recombinant SPA-1. IgG was purified on anion exchange column chromatography (Amersham Biosciences Corp., Piscataway, NJ, USA) from ascitic fluid of nude mice inoculated with the hybridoma in the peritoneal cavity.
The ABL kinase inhibitor imatinib was kindly provided by Novartis (Basel, Switzerland). Recombinant murine IL-3 and doxycycline (Dox) were purchased from Pepro Tech (Rocky Hill, NJ, USA) and Sigma (St Louis, MO, USA), respectively. Blasticidin-S was purchased from Funakoshi (Tokyo, Japan). 2 0 7 0 -bis-(2-carboxyethyl)-5-(and-6)-carboxy fluorescein acetoxymethyl ester (BCECF/AM) was purchased from Dojindo (Kumamoto, Japan). Antibodies against Rap1 (121), Raf-1 (C-12), B-Raf (H145), Abl (K-12), and glutathione S-transferase (GST) (B-14) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against Myc and phosphotyrosine (4G10) were purchased from Upstate Biotechnology (Lake Placid, NY, USA), and panRas (Ab-3) antibody was from Oncogene Research Products (Boston, MA, USA). Phosphospecific antibodies against MEK-1/2 (S217/221), Erk, AKT (ser473) and STAT5 (Tyr694) were from Cell Signaling (Beverly, MA, USA).
Establishment of Ton.B210. clones expressing SPA-1 Transfection for stable expression was performed essentially as described previously (Miura et al., 1993) . In brief, Ton.B210 cells were transfected with 10 mg of pSRa-myc-SPA-1 (Tsukamoto et al., 1999) along with 1 mg of pMAM2-BSD (Funakoshi, Tokyo, Japan) by electroporation at 960 mF and 300 V, followed by selection in medium containing blasticidin-S (Funakoshi). Clones were isolated by limiting dilution and examined for the expression of SPA-1 tagged with the Myc epitope by immunoblotting with anti-Myc. The clone expressing the highest level of Myc-tagged SPA-1, Ton.B210/SPA-1, was selected for the subsequent studies. However, for most of the experiments demonstrated, at least one other clone was additionally examined to confirm the validity of results.
To obtain pooled clones expressing SPA-1 and control pooled clones, Ton.B210 cells were electroporated with pSRamyc-SPA-1 or empty vector plasmid DNA along with pMAM2-BSD and selected with blasticidin-S as described above. Ten clones obtained from each transfection were arbitrarily selected and pooled for the subsequent experiments.
Immunoprecipitation and immunoblotting
For immunoprecipitation experiments, cells were lysed in a lysis buffer containing 1% Triton X-100, 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 mM bglycerophosphate, 1 mM sodium orthovanadate, and 10 mg/ml each of aprotinin and leupeptin. Cell lysates were subjected to immunoprecipitation and immunoblotting as described previously (Miura et al., 1994) . For immunoblot analysis of total cell lysates, samples were prepared by mixing an aliquot of cell lysates with an equal volume of 2 Â laemmli's sample buffer and heating at 1001C for 5 min.
GTPases activtivation assays and in vitro kinase assays for B-Raf and Raf-1 Small GTPase activation in cells was examined by using activation-specific probes for Ras (GST-Raf-RBD) and Rap1 (GST-RalGDS-RBD), as described previously (Arai et al., 2001) . In brief, cells were lysed and incubated with the fusion proteins precoupled to glutathione-agarose beads. GTPbound small GTPases were eluted from beads and analyzed by immunoblotting. Detected bands were analyzed densitometrically, and the experiments demonstrated are repeated at least three times with similar results.
Kinase activities of B-Raf and Raf-1 were measured as described previously (Bondzi et al., 2000; Mizuchi et al., 2005) . In brief, B-Raf or Raf-1 was immunoprecipitated and incubated with 20 mM ATP and GST-MEK-1 fusion protein (Upstate Biotechnology) at 301C for 15 min in a kinase reaction buffer containing 20 mM Tris (pH 7.4), 20 mM NaCl, 1 mM DTT, 10 mM MgCl 2 , and 1 mM MnCl 2 . The samples were resolved by SDS-PAGE and subjected to immunoblot analysis with antiphospho-MEK-1/2, followed by reprobing with anti-GST and anti-B-Raf or anti-Raf-1.
Cell proliferation assay and flow cytometric analysis of apoptosis For cell proliferation assay, cells were washed and resuspended at 1 Â 10 5 /ml in RPMI medium containing 10% FCS and indicated concentrations of IL-3 or Dox. Cells were plated in triplicate, and viable and nonviable cell numbers were determined by the trypan blue dye exclusion method after cultured for indicated times.
For flow cytometric analysis of apoptosis, cells were resuspended in Krishan's reagent (0.05 mg/ml PI, 0.1% Na citrate, 0.02 mg/ml ribonuclease A, 0.3% NP-40) at a concentration of 1 Â 10 6 cells/ml. After incubation for 30 min on ice, cells were analysed using a Becton Dickinson FACScan flow cytometer (Mountain View, CA, USA).
Cell adhesion assays
Adhesion assays were performed essentially as described previously (Arai et al., 1999 (Arai et al., , 2001 . In brief, cells were labeled with 5 mM BCECF/AM at 371C for 1 h. After being washed three times, fluorescently labeled cells were plated in quadruplicate on wells coated with 5 mg/ml fibronectin and incubated at 371C for 30 min. After wells were washed three times to remove unbound cells, cells remaining attached to the wells were measured by Cytofluor II fluorescent plate reader (PerSeptive Biosystems, Foster City, CA, USA). After subtraction of background cell binding to bovine serum albumin-coated wells, the percentage of adherent cells was determined by dividing the fluorescence intensity of the adherent cells by that of the initial cell input. All cell adhesion assays under 'Results' were repeated at least two times, and the results were reproducible.
